Endo International plc announced that the Company has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for collagenase clostridium histolyticum (CCH) for the treatment

This content is restricted to registered user. If you are an existing user, please log in. New users may register for free.

New User Registration
 
 
 
 
 
 
Please indicate that you agree to the Terms of Service *
*Required field